Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions

  • End date
    Dec 22, 2022
  • participants needed
  • sponsor
    Aventyn, Inc.
Updated on 27 June 2021
medical therapy
heart failure
pulmonary congestion
b-type natriuretic peptide
natriuretic peptide
coronary disease


Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinically, HF patients experience dyspnea, fatigue and diminished exercise tolerance, reflecting elevated left and/or right ventricular filling pressures and decreased cardiac output.


Heart failure patients are frequently hospitalized and have a high mortality rate and accounts for over 1 million hospital admissions yearly in the U.S. It is associated with a 2-year mortality rate of up to 40% to 50. The annual mortality rate for Acute Decompensated Heart Failure (ADHF) is 21%. ADHF initial hospitalization mortality rates range from 4% to 7%, with mortality as high as 22% in high risk patients. About 30% to 60% of ADHF patients are readmitted within 3-6 months after discharge from the first hospitalization. Inpatient treatment for ADHF consists of diuretics, vasodilators and inotropes. Hospital admissions for ADHF have increased precipitously during the past few decades and are projected to continue to increase in the future. To optimize patient outcomes and reduce the costs associated with this disorder, evidenced-based device and pharmacotherapy is essential. Diuretics, Beta blockers, RAAS blockers and cardiac resynchronization therapy are all useful to some extent in improving outcomes of quality of life and survival. In spite of optimized therapy, there is still relentless progression of disease and clinical exacerbations of fluid retention that precipitates hospital admissions and readmissions increasing poor quality outcomes as well as the cost burden for individual, hospitals, ACOs, payers and society as a whole. There is an urgent need to decrease hospital readmissions in Post Myocardial Infarction patients and subjects with recurrent CHF. This project will use patient empowerment and new technologies to increase QOL of patients as well as to reduce readmissions

Condition Heart failure, ADHF, Acute Myocardial Infarction, cardiac failure, Cardiac Disease, Heart disease, congestive heart disease, Congestive Heart Failure, Acute Decompensated Heart Failure, Heart Disease, Heart Failure
Treatment COMPASSION Digital Biomarker
Clinical Study IdentifierNCT04905160
SponsorAventyn, Inc.
Last Modified on27 June 2021


Yes No Not Sure

Inclusion Criteria

Men and women over 18 years of age are included. Eligible subjects must be
hospitalized with a primary diagnosis of ADHF or acute MI. The diagnosis of HF
is established by the presence of typical symptoms, signs, and objective
evidence of pulmonary congestion, elevated BNP or N-terminal pro B-type
natriuretic peptide (NT-pro BNP) or impaired cardiac function. Acute MI is
diagnosed by presence of chest pain, arm pain, or dyspnea with elevated
Troponin and/or EKG changes suggestive of Acute coronary syndrome requiring
intervention or optimal medical therapy

Exclusion Criteria

Study informed consent will be obtained before enrollment in the study for Phase 1 and Phase 2
All subjects 18 years or above will be a criteria for inclusion for Phase 1
For Phase 2, men and women 50 years or older with positive Covid19 antigen test and one other risk factor as mentioned in the comorbid section of workflow will be enrolled in the intervention arm of the study
For phase 2, subjects should be able to be randomized within 48 hours of Covid19 antigen positive status
Patients considered unreliable by the investigator concerning the requirements for follow-up visits
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note